NYSEAMERICAN : MTNB
Matinas BioPharma Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.48M |
| Enterprise Value | 724,074 |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 979,519 |
| Shares Outstanding | 979,519 |
| Shares Change (YoY) | +20.84% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.96% |
| Owned by Institutions (%) | 2.58% |
| Float | 763,074 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.36 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6,667.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -141.23% |
| Return on Assets (ROA) | -56.17% |
| Return on Invested Capital (ROIC) | -69.38% |
| Return on Capital Employed (ROCE) | -323.33% |
| Weighted Average Cost of Capital (WACC) | 15.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.65M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.08 |
| 52-Week Price Change | -92.49% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 33.10 |
| Average Volume (20 Days) | 84,301 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 49,432 |
| Short Previous Month | 29,399 |
| Short % of Shares Out | 5.05% |
| Short % of Float | 6.48% |
| Short Ratio (days to cover) | 0.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.67M |
| Pretax Income | -6.69M |
| Net Income | -7.31M |
| EBITDA | -6.66M |
| EBIT | -6.67M |
| Earnings Per Share (EPS) | -$17.87 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 761,000 |
| Total Debt | 6,000 |
| Net Cash | 755,000 |
| Net Cash Per Share | $0.77 |
| Equity (Book Value) | 1.80M |
| Book Value Per Share | 4.21 |
| Working Capital | -207,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.42M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5,000 |
| Net Borrowing | -8,000 |
| Free Cash Flow | -6.42M |
| FCF Per Share | -$6.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.84% |
| Shareholder Yield | -20.84% |
| Earnings Yield | -1,183.71% |
| FCF Yield | -434.06% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |